An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
about
Thalidomide and thalidomide analogues for maintenance of remission in Crohn's diseaseThalidomide and thalidomide analogues for induction of remission in Crohn's diseaseThalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study.Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients.Thalidomide and its derivatives: emerging from the wilderness.Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.Review article: medical treatment of moderate to severe Crohn's disease.Novel biological strategies in inflammatory bowel diseases.Management of ulcerative colitis and Crohn's disease.Recent advances in the medical therapy of Crohn's disease in childhood.Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature reviewThalidomide for inflammatory bowel disease: Systematic review.Review article: the role of non-biological drugs in refractory inflammatory bowel disease.Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesisGuidelines for medical treatment of Crohn's perianal fistulas: critical evaluation of therapeutic trials.Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.The clinical implications of thalidomide in inflammatory bowel diseases.Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-alpha.Successful use of thalidomide for refractory esophageal Crohn's disease.Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis.Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives
P2860
Q24241489-EF3F7AE9-86FF-43CB-ACFB-E4ECD9F4E00DQ24241766-A2A32BB7-2D3C-4D3D-9F0D-1ECBCB97ADE0Q33632574-9409FF56-3B86-428D-BCFC-68F2DE778C5BQ33760451-4624B6AF-8944-4561-B70B-D51EE09350B3Q35107977-5608E60B-2C03-4ADA-BBAD-DAAC85C9B70FQ35116177-C2CAFA16-5D56-4D1E-83E2-B759F9BDE9BCQ35145017-6E335845-7CAA-4779-A18B-55C614AE2F44Q35787653-C7F184C3-3402-4CB4-A535-688EB3B5A269Q36004867-EB0AA25C-0923-4DDF-BA07-F92E146A44B8Q36968175-B64C5D20-9B8E-4FBF-93AD-07AA63B1A3A5Q37257023-5A6FF448-55C3-410C-A392-63C20224E098Q37605607-2679E8A4-C499-4F53-A7E2-64F497948A73Q37817487-4AF31851-3D35-4823-96BA-E68BEA3AE3DCQ37862587-79FAD9C7-1204-49CA-BF17-9BFA3696C63FQ38370406-E896665F-3473-4D22-9888-68A96B9B4567Q38413494-E5E47AA1-9C15-4C3E-BD49-63E09AFBA481Q38417116-3EE8E17F-C553-4886-9C08-AE7669B5DA0EQ40249947-F9347429-8C10-4F89-B944-21B02CCB94DCQ45170573-27781A0F-57B4-4477-96AD-175D5D28535CQ47099231-CE71E283-7143-48BF-8519-8A82996574C3Q57076619-31765346-20EE-4BB3-B74E-E58258C76065
P2860
An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
An open-label study of thalido ...... ng refractory Crohn's disease.
@en
An open-label study of thalido ...... ng refractory Crohn's disease.
@nl
type
label
An open-label study of thalido ...... ng refractory Crohn's disease.
@en
An open-label study of thalido ...... ng refractory Crohn's disease.
@nl
prefLabel
An open-label study of thalido ...... ng refractory Crohn's disease.
@en
An open-label study of thalido ...... ng refractory Crohn's disease.
@nl
P2093
P2860
P1476
An open-label study of thalido ...... ng refractory Crohn's disease.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2036.2002.01273.X
P407
P577
2002-06-01T00:00:00Z